as 11-19-2025 3:27pm EST
Stocks
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
| Founded: | 2004 | Country: | Cayman Islands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 61.8M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 11.3K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $3.38 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ANL Breaking Stock News: Dive into ANL Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
GlobeNewswire
a month ago
MT Newswires
5 months ago
GlobeNewswire
7 months ago
Simply Wall St.
10 months ago
Simply Wall St.
a year ago
Simply Wall St.
a year ago
GlobeNewswire
a year ago
The information presented on this page, "ANL Adlai Nortye Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.